Proteasome Inhibitor May Help Prevent Organ Rejection

A new study shows that bortezomib, a proteasome inhibitor that is already approved by the FDA for treatment of multiple myeloma, reduces HLA antibodies in patients with CKD to a greater extent than traditional methods employing intravenous immunoglobulin. A 51.5% reduction in immunodominant antibodies was observed at 28 days with bortezomib treatment (1.3 mg/m2) and reductions increased with higher bortezomib dosing densities. Nineteen out of 44 treated patients (43.2%) were transplanted with low acute rejection rates (18.8%) and donor-specific antibody formation (12.5%). The findings are published in the American Journal of Transplantation.

Category:
Subcategory:
Body:

A new study shows that bortezomib, a proteasome inhibitor that is already approved by the FDA for treatment of multiple myeloma, reduces HLA antibodies in patients with CKD to a greater extent than traditional methods employing intravenous immunoglobulin. A 51.5% reduction in immunodominant antibodies was observed at 28 days with bortezomib treatment (1.3 mg/m2) and reductions increased with higher bortezomib dosing densities. Nineteen out of 44 treated patients (43.2%) were transplanted with low acute rejection rates (18.8%) and donor-specific antibody formation (12.5%). The findings are published in the American Journal of Transplantation.

Area(s) of Interest: